Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
19.1 USD | +3.52% |
|
+3.08% | +8.89% |
07-01 | Kiniksa Pharmaceuticals Files $400 Million Mixed Shelf | MT |
07-01 | Kiniksa Pharmaceuticals International, plc(NasdaqGS:KNSA) dropped from Russell 3000 Value Index | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
- According to Refinitiv, the company's ESG score for its industry is poor.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company appears highly valued given the size of its balance sheet.
- The company is highly valued given the cash flows generated by its activity.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+8.89% | 1.36B | C- | ||
+15.58% | 121B | B+ | ||
+16.60% | 110B | B+ | ||
+17.73% | 25.93B | B | ||
-24.33% | 19.27B | B+ | ||
-19.35% | 16.01B | A- | ||
-17.95% | 15.66B | B | ||
-48.32% | 14.89B | A- | ||
+58.78% | 14.47B | C+ | ||
+4.91% | 13.91B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- KNSA Stock
- Ratings Kiniksa Pharmaceuticals International, plc